JP2019513005A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513005A5 JP2019513005A5 JP2018540851A JP2018540851A JP2019513005A5 JP 2019513005 A5 JP2019513005 A5 JP 2019513005A5 JP 2018540851 A JP2018540851 A JP 2018540851A JP 2018540851 A JP2018540851 A JP 2018540851A JP 2019513005 A5 JP2019513005 A5 JP 2019513005A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- cancer
- antibody
- nucleic acid
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 23
- 210000004027 cell Anatomy 0.000 claims 11
- 108091008874 T cell receptors Proteins 0.000 claims 9
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 239000013604 expression vector Substances 0.000 claims 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims 1
- 108091054437 MHC class I family Proteins 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 210000000232 gallbladder Anatomy 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 108010028930 invariant chain Proteins 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662297495P | 2016-02-19 | 2016-02-19 | |
| US62/297,495 | 2016-02-19 | ||
| GB1602918.3 | 2016-02-19 | ||
| GBGB1602918.3A GB201602918D0 (en) | 2016-02-19 | 2016-02-19 | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| PCT/EP2017/053704 WO2017140897A1 (en) | 2016-02-19 | 2017-02-17 | Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers |
Related Child Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020163154A Division JP2021040628A (ja) | 2016-02-19 | 2020-09-29 | Ｎｈｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020163156A Division JP2021035361A (ja) | 2016-02-19 | 2020-09-29 | Ｎｈｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020163153A Division JP2021040627A (ja) | 2016-02-19 | 2020-09-29 | Ｎｈｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020163155A Division JP2021045124A (ja) | 2016-02-19 | 2020-09-29 | Ｎｈｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019513005A JP2019513005A (ja) | 2019-05-23 |
| JP2019513005A5 true JP2019513005A5 (OSRAM) | 2020-04-02 |
Family
ID=55752901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018540851A Pending JP2019513005A (ja) | 2016-02-19 | 2017-02-17 | Ｎｈｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US10293036B2 (OSRAM) |
| EP (2) | EP3885356A1 (OSRAM) |
| JP (1) | JP2019513005A (OSRAM) |
| KR (1) | KR20180111998A (OSRAM) |
| CN (1) | CN108713024A (OSRAM) |
| AU (1) | AU2017219851B2 (OSRAM) |
| BR (1) | BR112018015793A2 (OSRAM) |
| CA (1) | CA3014846A1 (OSRAM) |
| CR (4) | CR20200561A (OSRAM) |
| EA (1) | EA201891638A1 (OSRAM) |
| GB (1) | GB201602918D0 (OSRAM) |
| MA (2) | MA43075A1 (OSRAM) |
| MX (1) | MX2018009958A (OSRAM) |
| SG (3) | SG10202110292UA (OSRAM) |
| TW (1) | TW201734036A (OSRAM) |
| WO (1) | WO2017140897A1 (OSRAM) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201520544D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| CN114028549A (zh) * | 2016-02-19 | 2022-02-11 | 伊玛提克斯生物技术有限公司 | 用于nhl和其他癌症免疫治疗的新型肽和肽组合物 |
| JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
| GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| LT3652215T (lt) | 2017-07-14 | 2021-05-25 | Immatics Biotechnologies Gmbh | Pagerinta dvejopo savitumo polipeptido molekulė |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| CN111684062A (zh) | 2018-02-09 | 2020-09-18 | 伊玛提克斯美国公司 | 制造t细胞的方法 |
| DE102018107224A1 (de) | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| WO2020191172A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| KR20220029584A (ko) | 2019-05-27 | 2022-03-08 | 이매틱스 유에스 인코포레이티드 | 바이러스 벡터 및 입양 세포 요법에서 그 사용 |
| ES2991645T3 (es) | 2019-06-06 | 2024-12-04 | Immatics Biotechnologies Gmbh | Clasificación con contraselección mediante péptidos de secuencia similar |
| KR20230096914A (ko) * | 2019-07-22 | 2023-06-30 | 원스킨 인크. | 항노화 효과를 갖는 폴리펩타이드 및 그의 용도 |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| JP2023513605A (ja) * | 2020-02-14 | 2023-03-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | がんを処置するためのスプライシング由来抗原を含む組成物および方法 |
| JP2023515131A (ja) | 2020-02-24 | 2023-04-12 | イマティクス ユーエス，アイエヌシー． | がんおよび関連する悪性腫瘍の治療のためにｔ細胞を増殖させる方法 |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| WO2022040631A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| US20250352608A1 (en) * | 2020-11-02 | 2025-11-20 | Oneskin, Inc. | Polypeptides having anti-inflammatory effects and uses thereof |
| JP2024502034A (ja) | 2020-12-31 | 2024-01-17 | イマティクス ユーエス，アイエヌシー． | Ｃｄ８ポリペプチド、組成物、及びそれらの使用方法 |
| MX2023012899A (es) | 2021-05-05 | 2023-11-08 | Immatics Biotechnologies Gmbh | Polipeptidos de union a antigeno bma031 mejorados. |
| WO2023025851A1 (en) | 2021-08-24 | 2023-03-02 | Immatics US, Inc. | Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange |
| TW202332765A (zh) | 2021-09-20 | 2023-08-16 | 美商英麥提克斯股份有限公司 | 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡 |
| WO2023081925A1 (en) | 2021-11-08 | 2023-05-11 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| EP4514834A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| EP4514821A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| AU2023262596A1 (en) | 2022-04-28 | 2024-12-05 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2023215825A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| IE53176B1 (en) | 1978-12-22 | 1988-08-17 | Biogen Nv | Recombinant dna molecules and their method of production |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
| WO1994029347A1 (en) | 1993-06-03 | 1994-12-22 | Therapeutic Antibodies Inc. | Antibody fragments in therapy |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| WO1997026328A1 (en) | 1996-01-17 | 1997-07-24 | Imperial College Innovations Limited | Immunotherapy using cytotoxic t lymphocytes (ctl) |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| AU2001233114A1 (en) * | 2000-02-04 | 2001-08-14 | Aeomica, Inc. | Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence |
| JP2004503213A (ja) | 2000-03-27 | 2004-02-05 | テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド | １本鎖クラスｉ主要組織適合性複合体、それをコードする構築物およびそれを生成する方法 |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| AU2001275246B2 (en) | 2000-06-05 | 2006-06-29 | Altor Bioscience Corporation | T cell receptor fusions and conjugates and methods of use thereof |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| AU2003216341A1 (en) | 2002-02-20 | 2003-09-09 | Dyax Corporation | Mhc-peptide complex binding ligands |
| AU2003295311A1 (en) * | 2002-04-30 | 2004-05-04 | University Of North Carolina At Chapel Hill | Caterpiller gene family |
| AU2003228993A1 (en) * | 2002-05-10 | 2003-11-11 | Incyte Corporation | Proteins associated with cell growth, differentiation, and death |
| NZ539225A (en) | 2002-10-09 | 2006-09-29 | Avidex Ltd | Single chain recombinant T cell receptors |
| NZ539226A (en) | 2002-11-09 | 2008-09-26 | Medigene Ltd | T cell receptor display |
| JP2004229507A (ja) * | 2003-01-28 | 2004-08-19 | Japan Science & Technology Agency | 転写活性化因子 |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| US20080039413A1 (en) | 2003-10-21 | 2008-02-14 | Morris David W | Novel compositions and methods in cancer |
| ES2341802T3 (es) | 2005-09-05 | 2010-06-28 | Immatics Biotechnologies Gmbh | Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii. |
| GB0721686D0 (en) * | 2007-11-05 | 2007-12-12 | Medinnova As | Polypeptides |
| US20090263574A1 (en) | 2008-04-21 | 2009-10-22 | Quinn Daniel E | Method of restoring an article |
| US20100190656A1 (en) * | 2008-08-08 | 2010-07-29 | Integrated Diagnostics, Inc. | Breast Cancer Specific Markers and Methods of Use |
| US20110136113A1 (en) * | 2008-08-27 | 2011-06-09 | Sysmex Corporation | Marker for detecting il-17-producing helper t cell, and method for detecting il-17-producing helper t cell |
| US9410965B2 (en) * | 2009-09-17 | 2016-08-09 | Battelle Energy Alliance, Llc | Identification of discriminant proteins through antibody profiling, methods and apparatus for identifying an individual |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| GB201009222D0 (en) | 2010-06-02 | 2010-07-21 | Immatics Biotechnologies Gmbh | Improved cancer therapy based on tumour associated antigens derived from cyclin D1 |
| PL391627A1 (pl) * | 2010-06-25 | 2012-01-02 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Przeciwnowotworowe białko fuzyjne |
| CA2816225A1 (en) | 2010-10-26 | 2012-05-03 | Technion Research & Development Foundation Ltd. | Antibodies which bind soluble t-cell receptor ligands |
| NZ609916A (en) * | 2010-12-14 | 2015-03-27 | Immatics Biotechnologies Gmbh | Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
| WO2013057586A1 (en) | 2011-10-19 | 2013-04-25 | Oslo Universitetssykehus Hf | Compositions and methods for producing soluble t - cell receptors |
| BR112014018331A8 (pt) * | 2012-01-25 | 2017-07-11 | Univ Texas | Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação |
| US20150118244A1 (en) * | 2012-05-10 | 2015-04-30 | Bristol-Myers Squibb Company | Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients |
| JP2015533473A (ja) * | 2012-07-12 | 2015-11-26 | ペルシミューン，インコーポレイテッド | 個別のがんワクチン及び適応免疫細胞療法 |
| WO2014071978A1 (en) | 2012-11-08 | 2014-05-15 | Roche Diagnostics Gmbh | Nucleic acids encoding chimeric polypeptides for library screening |
| EP2808392A1 (en) | 2013-05-28 | 2014-12-03 | Rheinische Friedrich-Wilhelms-Universität Bonn | Aptamers and use of the aptamers in the diagnosis and treatment of cancer |
| TWI775117B (zh) * | 2013-08-05 | 2022-08-21 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（二） |
| SI3126381T2 (sl) | 2014-04-01 | 2022-05-31 | Biontech Cell&Gene Therapies Gmbh | Claudin-6-specifični imunoreceptorji in t-celični epitopi |
| GB201411037D0 (en) | 2014-06-20 | 2014-08-06 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL) |
| GB201507719D0 (en) * | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| GB201511546D0 (en) * | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| AU2017254477A1 (en) * | 2016-04-18 | 2018-11-01 | Jennifer G. ABELIN | Improved HLA epitope prediction |
-
2016
- 2016-02-19 GB GBGB1602918.3A patent/GB201602918D0/en not_active Ceased
-
2017
- 2017-02-17 SG SG10202110292U patent/SG10202110292UA/en unknown
- 2017-02-17 SG SG11201806577UA patent/SG11201806577UA/en unknown
- 2017-02-17 CN CN201780011919.2A patent/CN108713024A/zh active Pending
- 2017-02-17 MX MX2018009958A patent/MX2018009958A/es unknown
- 2017-02-17 CR CR20200561A patent/CR20200561A/es unknown
- 2017-02-17 KR KR1020187026352A patent/KR20180111998A/ko not_active Withdrawn
- 2017-02-17 US US15/436,385 patent/US10293036B2/en active Active
- 2017-02-17 MA MA43075A patent/MA43075A1/fr unknown
- 2017-02-17 JP JP2018540851A patent/JP2019513005A/ja active Pending
- 2017-02-17 MA MA044228A patent/MA44228A/fr unknown
- 2017-02-17 TW TW106105250A patent/TW201734036A/zh unknown
- 2017-02-17 WO PCT/EP2017/053704 patent/WO2017140897A1/en not_active Ceased
- 2017-02-17 CA CA3014846A patent/CA3014846A1/en active Pending
- 2017-02-17 EP EP21165092.4A patent/EP3885356A1/en not_active Withdrawn
- 2017-02-17 CR CR20200560A patent/CR20200560A/es unknown
- 2017-02-17 EA EA201891638A patent/EA201891638A1/ru unknown
- 2017-02-17 EP EP17705891.4A patent/EP3416980A1/en not_active Withdrawn
- 2017-02-17 BR BR112018015793A patent/BR112018015793A2/pt not_active IP Right Cessation
- 2017-02-17 CR CR20200562A patent/CR20200562A/es unknown
- 2017-02-17 AU AU2017219851A patent/AU2017219851B2/en not_active Ceased
- 2017-02-17 SG SG10202007962RA patent/SG10202007962RA/en unknown
- 2017-02-17 CR CR20180346A patent/CR20180346A/es unknown
-
2018
- 2018-11-15 US US16/192,391 patent/US10335475B2/en active Active
- 2018-11-15 US US16/192,422 patent/US10314898B2/en active Active
- 2018-11-16 US US16/193,334 patent/US10363295B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019513005A5 (OSRAM) | ||
| JP2019516663A5 (OSRAM) | ||
| JP2020191862A5 (OSRAM) | ||
| JP2020182458A5 (OSRAM) | ||
| JP2020198875A5 (OSRAM) | ||
| JP2021101700A5 (OSRAM) | ||
| JP2019536426A5 (OSRAM) | ||
| HRP20202019T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora | |
| HRP20210698T1 (hr) | Peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma dojke i drugih karcinoma | |
| JP2020506690A5 (OSRAM) | ||
| HRP20210709T1 (hr) | Peptidi i kombinacija peptida za imunoterapiju protiv karcinoma prostate i druge vrste karcinoma | |
| HRP20201281T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv epitelnog karcinoma jajnika i drugih karcinoma | |
| RU2020113032A (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
| AR121383A2 (es) | Péptidos y combinación de péptidos y andamiajes para su uso en inmunoterapia contra carcinoma de células renales (rcc) y otros cánceres | |
| JP2020516681A5 (OSRAM) | ||
| JP2024099580A5 (OSRAM) | ||
| JP2011520436A5 (OSRAM) | ||
| HRP20230512T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma jajnika i drugih karcinoma | |
| JP2019515653A5 (OSRAM) | ||
| JP2019502360A5 (OSRAM) | ||
| JP2019520038A5 (OSRAM) | ||
| FI3273986T3 (fi) | Uusia peptidejä ja peptidien yhdistelmiä käytettäväksi immunoterapiassa eri syöpiä vastaan | |
| JP2016501829A5 (OSRAM) | ||
| HRP20210076T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma ezofagusa i drugih karcinoma | |
| HRP20192262T1 (hr) | Nova imunoterapija protiv nekoliko tumora, kao što su rak pluća, uključujući mikrocelularni karcinom pluća (nsclc) |